Immune Thrombocytopenia (ITP) Market in China 2023
Immune thrombocytopenia (ITP) is a rare autoimmune disorder that affects the blood's ability to clot properly. It is caused by the immune system mistakenly attacking and destroying platelets, which are necessary for blood clotting. This leads to a decrease in the number of platelets in the blood, resulting in easy bruising and bleeding, particularly in the skin and mucous membranes. ITP is usually diagnosed through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment for ITP typically depends on the severity of the symptoms. Mild cases may not require treatment, while more severe cases may require medication to increase the number of platelets in the blood, such as corticosteroids, immunosuppressants, or intravenous immunoglobulin. In severe cases, removal of the spleen (splenectomy) may be recommended to reduce the destruction of platelets. The immune thrombocytopenia market in China is projected to rise by USD 690.6 million by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 21.74 percent during the forecast period.
This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on immune thrombocytopenia can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.
The immune thrombocytopenia market in China comprises only a handful of players such as 3SBio Inc., Novartis International AG.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Immune Thrombocytopenia Market
Identify segments/areas to invest in over the forecast period in the China Immune Thrombocytopenia Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on immune thrombocytopenia can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.
The immune thrombocytopenia market in China comprises only a handful of players such as 3SBio Inc., Novartis International AG.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Immune Thrombocytopenia Market
Identify segments/areas to invest in over the forecast period in the China Immune Thrombocytopenia Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Part 1. Summary
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Immune thrombocytopenia market overview
Part 4. Market breakdown by region
Central South China
East China
North China
Northeast China
Northwest China
Southwest China
Part 5. Key companies
3SBio Inc.
Novartis International AG
Part 6. Methodology
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Immune thrombocytopenia market overview
Part 4. Market breakdown by region
Central South China
East China
North China
Northeast China
Northwest China
Southwest China
Part 5. Key companies
3SBio Inc.
Novartis International AG
Part 6. Methodology
